TG Therapeutics (NASDAQ:TGTX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday.

Several other research firms have also weighed in on TGTX. ValuEngine lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. HC Wainwright reiterated a “buy” rating and issued a $33.00 price objective (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. SunTrust Banks reiterated a “buy” rating and issued a $28.00 price objective on shares of TG Therapeutics in a research note on Tuesday, October 3rd. B. Riley reiterated a “buy” rating and issued a $21.50 price objective on shares of TG Therapeutics in a research note on Monday, December 11th. Finally, Raymond James Financial reiterated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. TG Therapeutics presently has an average rating of “Buy” and an average target price of $25.50.

TG Therapeutics (TGTX) traded down $0.78 during trading hours on Thursday, hitting $9.88. 2,099,636 shares of the stock traded hands, compared to its average volume of 1,250,299. The company has a market cap of $697.69, a price-to-earnings ratio of -5.12 and a beta of 1.30. TG Therapeutics has a 12 month low of $4.10 and a 12 month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.05). The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. analysts forecast that TG Therapeutics will post -1.87 EPS for the current fiscal year.

In related news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the sale, the chief financial officer now owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 16.70% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. grew its position in TG Therapeutics by 44.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock valued at $3,658,000 after purchasing an additional 111,155 shares during the period. Ameriprise Financial Inc. boosted its holdings in TG Therapeutics by 150.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 277,235 shares of the biopharmaceutical company’s stock worth $2,786,000 after acquiring an additional 166,434 shares during the last quarter. Franklin Resources Inc. boosted its holdings in TG Therapeutics by 20.6% during the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after acquiring an additional 398,916 shares during the last quarter. Kennedy Capital Management Inc. boosted its holdings in TG Therapeutics by 151.6% during the 2nd quarter. Kennedy Capital Management Inc. now owns 565,178 shares of the biopharmaceutical company’s stock worth $5,680,000 after acquiring an additional 340,545 shares during the last quarter. Finally, State Street Corp boosted its holdings in TG Therapeutics by 274.4% during the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after acquiring an additional 1,933,896 shares during the last quarter. 50.41% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/14/bidaskclub-upgrades-tg-therapeutics-tgtx-to-hold.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.